Lundbeck Research USA, Inc., 215 College Road, 07652 Paramus, NJ, United States.
Lundbeck Research USA, Inc., 215 College Road, 07652 Paramus, NJ, United States.
Eur Neuropsychopharmacol. 2014 Jan;24(1):160-71. doi: 10.1016/j.euroneuro.2013.07.001. Epub 2013 Aug 2.
We previously reported that the investigational multimodal antidepressant, vortioxetine, reversed 5-HT depletion-induced memory deficits while escitalopram and duloxetine did not. The present report studied the effects of vortioxetine and the potential impact of its 5-HT1A receptor agonist and 5-HT3 receptor antagonist properties on 5-HT depletion-induced memory deficits. Recognition and spatial working memory were assessed in the object recognition (OR) and Y-maze spontaneous alternation (SA) tests, respectively. 5-HT depletion was induced in female Long-Evans rats using 4-cholro-DL-phenylalanine methyl ester HCl (PCPA) and receptor occupancies were determined by ex vivo autoradiography. Rats were acutely dosed with vortioxetine, ondansetron (5-HT3 receptor antagonist) or flesinoxan (5-HT1A receptor agonist). The effects of chronic vortioxetine administration on 5-HT depletion-induced memory deficits were also assessed. 5-HT depletion reliably impaired memory performance in both the tests. Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) ≤0.1mg/kg (∼80% 5-HT3 receptor occupancy; OR) and ≤3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ∼15%, 60%, 95%) in SA. Ondansetron exhibited a MED ≤3.0μg/kg (∼25% 5-HT3 receptor occupancy; OR), but was inactive in the SA test. Flesinoxan had a MED ≤1.0mg/kg (∼25% 5-HT1A receptor occupancy; SA); only 1.0mg/kg ameliorated deficits in the NOR. Chronic p.o. vortioxetine administration significantly improved memory performance in OR and occupied 95%, 66%, and 9.5% of 5-HT3, 5-HT1B, and 5-HT1A receptors, respectively. Vortioxetine's effects on SA performance may involve 5-HT1A receptor agonism, but not 5-HT3 receptor antagonism, whereas the effects on OR performance may involve 5-HT3 receptor antagonism and 5-HT1A receptor agonism.
我们之前曾报道过,研究性多模式抗抑郁药文拉法辛能逆转 5-HT 耗竭诱导的记忆缺陷,而艾司西酞普兰和度洛西汀则不能。本报告研究了文拉法辛的作用及其作为 5-HT1A 受体激动剂和 5-HT3 受体拮抗剂的潜在影响对 5-HT 耗竭诱导的记忆缺陷的影响。通过物体识别(OR)和 Y 迷宫自发交替(SA)测试分别评估识别和空间工作记忆。使用 4-氯-DL-苯丙氨酸甲酯盐酸盐(PCPA)诱导雌性长耳大仓鼠的 5-HT 耗竭,并通过离体放射自显影术测定受体占有率。大鼠急性给予文拉法辛、昂丹司琼(5-HT3 受体拮抗剂)或 flesinoxan(5-HT1A 受体激动剂)。还评估了慢性文拉法辛给药对 5-HT 耗竭诱导的记忆缺陷的影响。5-HT 耗竭可靠地损害了两种测试中的记忆表现。文拉法辛以剂量依赖性方式逆转 PCPA 诱导的记忆缺陷,最小有效剂量(MED)≤0.1mg/kg(约 80%5-HT3 受体占有率;OR)和≤3.0mg/kg(5-HT1A、5-HT1B、5-HT3 受体占有率:约 15%、60%、95%)在 SA。昂丹司琼表现出 MED≤3.0μg/kg(约 25%5-HT3 受体占有率;OR),但在 SA 试验中无效。fleinoxan 的 MED≤1.0mg/kg(约 25%5-HT1A 受体占有率;SA);只有 1.0mg/kg 改善了 NOR 中的缺陷。慢性口服文拉法辛给药显著改善了 OR 中的记忆表现,分别占据了 5-HT3、5-HT1B 和 5-HT1A 受体的 95%、66%和 9.5%。文拉法辛对 SA 表现的影响可能涉及 5-HT1A 受体激动作用,但不涉及 5-HT3 受体拮抗作用,而对 OR 表现的影响可能涉及 5-HT3 受体拮抗作用和 5-HT1A 受体激动作用。